Joanna Broder

In patients with SLE, 62.1% did not adhere to their medication regimens and 35% of patients demonstrated a depressed mood.

These results highlight the importance of a multidisciplinary team for treating patients with rheumatoid arthritis.

Research confirmed the increased burden of SLE in black, Asian, and Hispanic women compared with white women.

The selective Janus kinase-1 inhibitor filgotinib has shown initial efficacy and adequate safety for the treatment of rheumatoid arthritis.

For patients with active rheumatoid arthritis who are not responding to DMARDs, sirukumab may represent a safe and effective treatment.

Patients recently diagnosed with rheumatoid arthritis showed similar efficacy and safety outcomes during a 4-year follow-up period after receiving treatment with COBRA-light or COBRA therapy.

Infections and respiratory tract diseases are linked to a greater risk for idiopathic inflammatory myopathy.

Mannose-binding lectin of the complement system may contribute to the development of clinical manifestations in SLE.

Herpes zoster vaccine shown to be safe in patients with rheumatoid arthritis.

The risk for cardiovascular events was higher in patients with Takayasu’s arteritis.